Abstract

Objective: Obteinment and characterizing polymeric nanocapsules of simvastatin (SV), and investigating their action in an experimental model of peritoneal fibrosis induced in a rat by the infusion of peritoneal dialysis (PD) solution.
 Methods: Poly (ε-caprolactone) nanocapsules containing SV (NC-SV) were prepared by interfacial deposition of a preformed polymer. A suspension of nanoparticles with no drug was prepared as negative control. The average particle size and polydispersity index were measured by photon correlation spectroscopy. The morphological and surface evaluation of prepared nanocapsules was performed using field emission scanning electron microscopy. The ultra-high performance liquid chromatography with photodiode array detection method was used to evaluate the drug encapsulation efficiency. The release profiles of SV from polymeric nanocapsules were obtained by dialysis diffusion technique. The Animal Study was performed in a total of 48 male Wistar rats (Rattus norvegicus) divided in four groups: Sham, PD group, SV group, and Simvastatin-loaded nanocapsules group (NC-SV). After 28 days, tissue samples were surgically removed from the abdominal to perform histological and immunohistochemistry analysis. The statistical analysis was performed by one-way ANOVA followed by Bonferroni test, or by Kruskal–Wallis.
 Results: NC-SV presented suitable particle parameters with a mean particle size of 332 nm, and an encapsulation efficiency of 99.87±0.46%. The expression of tumor necrosis factor-alpha (TNF-α) was significantly different in NC-SV group.
 Conclusion: SV-loaded nanocapsules for controlled drug delivery were suitably prepared. This nanoformulation remarkable decreased the TNF-α tissue expression even at low SV dose in a chronic PD model.

Highlights

  • The prevalence of chronic kidney disease (CKD) is increasing worldwide and reached 2204 patients per million inhabitants in the USA

  • Nanoscale dimensions were registered for nanocapsules containing SV (NC-SV) (a) and nanoparticles with no drug (NC-N) (b) when their images were assessed by field emission scanning electron microscopy (FESEM) (Fig. 1)

  • SV showed an appropriate separation at short retention time of 1.71 min

Read more

Summary

Introduction

The prevalence of chronic kidney disease (CKD) is increasing worldwide and reached 2204 patients per million inhabitants in the USA. The main obstacles to the long-term PD treatment are both infections and pathological changes in the peritoneal membrane exposed to dialysis solutions (DS), which affect 50% of PD patients. These patients may progress to the encapsulating peritonitis (EP) depending on the treatment time interval [3]. EP is a disease with high mortality, which reaches 74% in patients with severe forms [4]. It can occur in children on PD, showing a similar prevalence to adults [5,6]. The current prevalence of EP may be higher than that reported

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call